2023-05-18 02:59:43 ET
- Clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, Addex Therapeutics ( NASDAQ: ADXN ) received Nasdaq notice that, for the last thirty consecutive business days, the bid price for the company’s ADSs had closed below the minimum $1.00 per ADS requirement for continued listing.
- The company is provided an initial period of 180 calendar days to regain compliance.
- Compliance will be achieved if the bid price of the ADSs closes at $1.00 per ADS or more for a minimum of ten consecutive business days.
- The stock price declined 3.8% on Wednesday late hours.
For further details see:
Addex Therapeutics receives Nasdaq non-compliance notice